Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A G Awad

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
International Clinical Psychopharmacology|May 1, 1996
Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcomeA G Awad, L N Voruganti, R J Heslegrave, et al.
International Clinical Psychopharmacology|September 1, 1995
Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of lifeA G Awad, T P Hogan, L N Voruganti, et al.
Schizophrenia Research|February 7, 1997
Neurocognitive deficits and neurological signs in schizophreniaA H Wong, L N Voruganti, R J Heslegrave, et al.
International Journal of Psychiatry in Clinical Practice|June 19, 2014
Patient satisfaction and acceptability of long-term treatment with quetiapineJ S Hellewell, A H Kalali, S J Langham, et al.
Pharmacoeconomics|August 18, 2000
Assessing health utilities in schizophrenia. A feasibility studyL N Voruganti, A G Awad, L K Oyewumi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 30, 2001
Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imagingL Voruganti, P Slomka, P Zabel, et al.
Schizophrenia Research|August 31, 2007
Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapineL P Voruganti, A G Awad, G Parker, et al.
Schizophrenia Research|September 4, 2007
Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) studyL P Voruganti, Z Punthakee, R J Van Lieshout, et al.
Canadian Medical Association Journal|June 1, 1981
Renal function in patients receiving long-term lithium therapyP R Uldall, A G Awad, W O McCormick, et al.
CNS Spectrums|August 23, 2005
An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklistsS G Dott, P Weiden, P Hopwood, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
International Clinical Psychopharmacology|May 1, 1996
Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcomeA G Awad, L N Voruganti, R J Heslegrave, et al.
International Clinical Psychopharmacology|September 1, 1995
Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of lifeA G Awad, T P Hogan, L N Voruganti, et al.
Schizophrenia Research|February 7, 1997
Neurocognitive deficits and neurological signs in schizophreniaA H Wong, L N Voruganti, R J Heslegrave, et al.
International Journal of Psychiatry in Clinical Practice|June 19, 2014
Patient satisfaction and acceptability of long-term treatment with quetiapineJ S Hellewell, A H Kalali, S J Langham, et al.
Pharmacoeconomics|August 18, 2000
Assessing health utilities in schizophrenia. A feasibility studyL N Voruganti, A G Awad, L K Oyewumi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 30, 2001
Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imagingL Voruganti, P Slomka, P Zabel, et al.
Schizophrenia Research|August 31, 2007
Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapineL P Voruganti, A G Awad, G Parker, et al.
Schizophrenia Research|September 4, 2007
Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) studyL P Voruganti, Z Punthakee, R J Van Lieshout, et al.
Canadian Medical Association Journal|June 1, 1981
Renal function in patients receiving long-term lithium therapyP R Uldall, A G Awad, W O McCormick, et al.
CNS Spectrums|August 23, 2005
An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklistsS G Dott, P Weiden, P Hopwood, et al.
Pageof 6